Anti-NMDA-Receptor Encephalitis: Case Series and Analysis of the Effects of Antibodies
Lancet Neurol 7:1091-1098, Dalmau,J.,et al, 2008
Treatment-Responsive Subacute Limbic Encephalitis and NMDA Receptor Antibodies in a Man
Neurol 70:728-729, Novillo-Lopez,M.E.,et al, 2008
Anti-NMDA Receptor Encephalitis in Japan: Long-Term Outcome Without Tumor Removal
Neurol 70:504-511,500, Iizuka,T.,et al, 2008
The Writing on the Wall
Lancet 372:344, Wilder-Smith,E.P. &Ng,E.S., 2008
Clinicopath Conf., Anti-MNDAR Antibody Mediated Paraneoplastic Limbic Encephalitis Associated With Ovarian Teratoma
NEJM 359:842-853, Case 26-2008, 2008
Neuro-Ophthalmologic Manifestations of Paraneoplastic Syndromes
J Neuro-Ophthalmol 28:58-68, Ko,M.W.,et al, 2008
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Arch Neurol 63:49-54, Reisberg,B.,et al, 2006
Survival after Treatment of Rabies with Induction of Coma
NEJM 352:2508-2514,2549, Willoughby,Jr.,R.E.,et al, 2005
Aromatic L-Amino Acid Decarboxylase Deficiency
Neurol 62:1058-1065, Pons,R.,et al, 2004
Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004
Memantine in Moderate-to-Severe Alzheimer's Disease
NEJM 348:1333-1341, Reisberg,B.,et al, 2003
Tolerability of Memantine in Combination with Cholinesterase Inhibitors in Dementia Therapy
Int Clin Psychopharm 18:81-85, Hartmann,S.& Mobius, H.J., 2003
Progression of Ischaemic Stroke and Excitotoxic Aminoacids
Lancet 349:79-83, Castillo,J.,et al, 1997
Wernicke's Encephalopathy:An Excitotoxicity Hypothesis
Metabolic Brain Disease 12:183-192, McEntee,W.J., 1997
Excess Glutamate Levels in the Cerebrospinal Fluid Predict Clinical Outcome of Bacterial Meningitis
Arch Neurol 53:992-996, Spranger,M.,et al, 1996
Dose-Ranging Study of Riluzole in Amyotrophic Lateral Sclerosis
Lancet 347:1425-1431, Lacomblez,L.,et al, 1996
Clinical Experience with Excitatory Amino Acid Antagonist Drugs
Stroke 26:503-513, Muir,K.W.&Lees,K.R., 1995
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
NEJM 330:613-622, Lipton,S.A.&Rosenberg,P.A., 1994
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994
Prophylactic Neuroprotection for Cerebral Ischemia
Stroke 25:1075-1080, Fisher,M.,et al, 1994
The Ischemic Penumbra, Injury Thresholds, and the Therapeutic Window for Acute Stroke
Ann Neurol 36:553-554, 5571994., Ginsberg,M.D.&Pulsinelli,W.A., 1994
Schizophrenia as a Brain Disease
Arch Neurol 50:1096-1097, Williamson,P.C., 1993
Evolving Toward Effective Therapy for Acute Ischemic Stroke
JAMA 270:360-364, Fisher,M.&Bogousslavsky,J., 1993
Extracellular Hippocampal Glutamate and Spontaneous Seizure in the Conscious Human Brain
Lancet 341:1607-1610, 16271993., During,M.J.&Spencer,D.D., 1993
Cell Culture Evidence for Neuronal Degeneration in ALS to Glutamate AMPA/Kainate Receptors
Lancet 341:265-268, Couratier,P.,et al, 1993
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992
Do NMDA Antagonists Prevent Neuronal Injury? No
Arch Neurol 49:420-421, Buchan,A.M., 1992
Decreased Glutamate Transport by the Brain and Spinal Cord in Amyotrophic Lateral Sclerosis
NEJM 326:1464-1468, 14931992., Rothstein,J.D.,et al, 1992
N-Methyl-D-Aspartate Antagonists in the Treatment of Parkinson's Disease
Arch Neurol 48:977-981, Greenamyre,J.T.&O'Brien,C.F., 1991
Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome after Embolic Stroke
Arch Neurol 48:1235-1238, Zivin,J.A.&Mazzarella,V., 1991
The Bioloigcal Basis for the Treatment of Acute Stroke
Neurol 41:1867-1873, Scheinberg,P., 1991
Migraine-Related Stroke in Childhood
Lancet 337:825-826, , 1991
Amelioration of Vincristine Neurotoxicity by Glutamic Acid
Am J Med 84:1016-1022, Jackson,D.V.,et al, 1988
The Role of Glutamate in Neurotransmission & in Neurologic Disease
Arch Neurol 43:1058-1063, Greenamyre,J.T., 1986
Glutamate & the Pathophysiology of Hypoxic-Ischemic Brain Damage
Ann Neurol 19:105-111, Rothman,S.M.&Olney,J.W., 1986
Acute Hepatic Failure Associated with the Use of Sodium Valproate
NEJM 300:962-966, Suchy,F.J.,et al, 1979
Valproic Acid, Review of a New Antiepileptic Drug
Arch Neurol 36:393-398, Bruni,J.,et al, 1979
Possible Psychiatric Reactions to Monosodium Glutamate
NEJM 299:902, Colman,A.D., 1978
Effect of Valproic Acid on Hepatic Function
Neurol 28:961-964, Willmore,L.J.,et al, 1978
Long-term Therapy of Myoclonus & Other Neurologic Disorders with L-5-Hydroxytryptophan & Carbidopa
NEJM 296:70, VanWoert,M.H.,et al, 1977
Peripheral Neuropathy, A Review
JAMA 335:255-266, Mauermann,M.L. & Staff,N.P., 2026
A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion
NEJM 394:442-450, Ryan,S.J.,et al, 2026
Endovascular Therapy for Medium-Vessel Occlusion Stroke - Narrowing the Target Population
NEJM 394:1955-1957,1894, Ospel,J.M. & Hill, M.D., 2026
Creutzfeldt-Jakob-Like Presentation in Anti-AMPAR Encephalitis
Ann Neurol 99:1466-1467, Durbano,K.et al, 2026
Anticoagulation or Antiplatelet Therapy for Device-Detected Atrial Fibrillation
NEJM 392:1749-1751, Gorey,S., 2025
Aspirin Continuation or Discontinuation in Surgically Treated Chronic Subdural Hematoma, A Randomized Clinical Trial
JAMA Neurol 82:551-559, Kamenova,M.,et al, 2025
Trident Sign in GFAP-Associated Meningoencephalomyelitis
Neurol 106:e214566, Mallett,N.S.,et al, 2025
Endovascular Treatment in Acute Ischemic Stroke Due to Occlusion of Medium or Distal Vessels
Neurol 105:e214015, Palaiodimou,L.,et al, 2025
Unmasking Cerebrotendinous Xanthomatosis, Clinical Recognition of a Treatable Cause of Progressive Ataxia
Neurol 105:e214099, Mizutani,H.,et al, 2025
Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke
NEJM 393:1191-1201, Tao,C.,et al, 2025